Skip to main content
Year archive

Swedish Orphan Biovitrum — 2019 filings

All 38 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2019, sourced directly from the official regulator.

38 Filings
2019 Period
2019 filings (38)
Filing Released Lang
Sobi successfully completes acquisition of Dova Pharmaceuticals
M&A Activity
2019-11-12 English
Sobi har framgångsrikt slutfört förvärvet av Dova Pharmaceuticals
M&A Activity
2019-11-12 Swedish
Sobi successfully completes tender offer for all outstanding shares of Dova Pharmaceuticals
Delisting Announcement
2019-11-09 English
Sobi har framgångsrikt slutfört uppköpserbjudandet avseende samtliga utestående aktier i Dova Pharmaceuticals
M&A Activity
2019-11-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-10-31 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-10-31 English
Sobi inleder uppköpserbjudande avseende samtliga utestående aktier i Dova Pharmaceuticals
M&A Activity
2019-10-11 Swedish
Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals
M&A Activity
2019-10-11 English
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2019-09-30 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2019-09-30 Swedish
Sobi strengthens haemophilia position with potential once-weekly haemophilia A treatment
Regulatory Filings
2019-09-29 English
Sobi stärker position inom hemofili med potentiell veckovis behandling av hemofili A
Regulatory Filings
2019-09-29 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-08-30 English
Sobi completes acquisition of emapalumab and related assets
M&A Activity
2019-07-18 English
Sobi slutför förvärvet av emapalumab och relaterade tillgångar
M&A Activity
2019-07-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-07-17 English
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-07-17 Swedish
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Transaction in Own Shares
2019-07-16 Swedish
The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme
Transaction in Own Shares
2019-07-16 English
Sobi strengthens focus and increases investments in late-stage development in Haematology and Immunology
Management Reports
2019-06-12 English
Sobi stärker fokus och ökar investeringar i utvecklingsprojekt i sen fas inom Haematology och Immunology
Share Issue/Capital Change
2019-06-12 Swedish
Bulletin from Swedish Orphan Biovitrum’s (“Sobi”) Annual General Meeting (AGM)
AGM Information
2019-05-09 English
Kommuniké från Swedish Orphan Biovitrums (”Sobi”) årsstämma
AGM Information
2019-05-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-25 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-25 English
Annual Report 2018
Annual Report FY 2018
2019-04-18 Swedish
Annual Report 2018
Annual Report FY 2018
2019-04-18 English
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2019-04-03 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2019-04-03 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q4 2018
2019-02-20 English
Earnings Release 2018
Earnings Release Q4 2018
2019-02-20 Swedish
Sobi publicerar bokslutskommunikén för 2018
Earnings Release Q4 2018
2019-02-20 Swedish
Sobi publishes the report for the fourth quarter and full-year 2018
Audit Report / Information FY 2018
2019-02-20 English
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2019-01-31 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2019-01-31 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-30 English
Sobi™ completes acquisition of Synagis® US rights from AstraZeneca and exercises authorisation to issue shares
M&A Activity
2019-01-24 English
Sobi™ slutför förvärvet av USA-rättigheterna till Synagis® från AstraZeneca och utnyttjar bemyndigande att emittera aktier
M&A Activity
2019-01-24 Swedish